3.90
+4.56%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kyntra Bio
From its filings with the US Securities and Exchange Commission
Kyntra Bio is based in San Francisco, California. Its shares trade on Nasdaq under the ticker KYNB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $6.4m and net income of $183.5m. At that date it held total assets of $119.6m and shareholders' equity of −$30.0m.
Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia.
We are developing FG-3246, a potential first-in-class antibody-drug conjugate (“ADC”) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (“PET”) biomarker and imaging agent. We initiated a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory sub-study of FG-3180, in the third quarter of 2025.
We and our collaboration partners developed roxadustat (爱瑞卓®, EVRENZOTM), which is currently approved in Europe, Japan, the People’s Republic of China (“China”), and numerous other countries for the treatment of anemia in chronic kidney disease (“CKD”) patients on dialysis and not on dialysis.
On August 29, 2025, we closed the sale of our China operations through FibroGen International (Hong Kong) Ltd. (“FibroGen International”) to AstraZeneca Treasury Limited pursuant to the share purchase agreement entered into by the Company and AstraZeneca Treasury Limited on February 20, 2025, as amended (the “Share Purchase Agreement”) for a total consideration of $220.4 million comprised of $85.0 million in enterprise value and $135.4 million in net cash held in China. AstraZeneca AB (“AstraZeneca”) was our long-time commercialization partner for roxadustat in greater China.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Nov 2014
- Employees
- 34
- Website
- fibrogen.com ↗
- Head office
- 350 BAY STREET, SAN FRANCISCO, CA, 94133
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. James SchoeneckIndependent Chairman of the Board, since 2010$189,360
- Mr. Thane WettigChief Executive Officer, Director, since 2020$2.6m
- Mr. David DeluciaChief Financial Officer$686,153
- Ms. Christine ChungSenior Vice President, China Operations$1.2m
- Dr. Michael KauffmanDirector
- Mr. Jeffrey EdwardsIndependent Director$143,735
- Dr. Maykin HoIndependent Director$132,485
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 83
- Environment
- 90
- Social
- 99
- Governance
- 59
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- FibroGen employs 599 full-time employees in San Francisco for biopharmaceutical development.
- Roxadustat is in clinical development for anemia associated with chronic kidney disease CKD.
- Pamrevlumab is in clinical development for idiopathic pulmonary fibrosis IPF and pancreatic cancer.
Weaknesses
- FibroGen has 34 employees in the US as a biotechnology company.
- FibroGen's IPO was on 14 November 2014 in the Health Care sector.
- FibroGen's headquarters is in San Francisco, California.
Opportunities
- FibroGen's roxadustat targets anemia in chronic kidney disease CKD patients.
- FibroGen's pamrevlumab is in clinical development for coronavirus COVID-19 treatment.
- FibroGen's biopharmaceutical focus on hypoxia-inducible factor HIF biology.
Threats
- FibroGen's roxadustat faces competition in anemia treatments for chronic kidney disease CKD.
- FibroGen's pamrevlumab faces challenges in clinical development for IPF and cancer.
- FibroGen's biotechnology sector has high regulatory hurdles for new drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.